SAN FRANCISCO, June 27, 2022 /PRNewswire/ — New market research published by Global Industry Analysts Inc., (GIA), the leading market research firm, today released its report titled “Critical Care Therapeutics – Global Market Trajectory and Analysis”. The report presents new insights into the opportunities and challenges in a significantly transformed post COVID-19 market.
FACTS AT A GLANCE
What’s new for 2022?
Global competitiveness and percentage market shares of main competitors
Market presence in multiple geographies – Strong/Active/Niche/Trivial
Peer-to-peer collaborative online interactive updates
Access to our digital archives and the MarketGlass research platform
Free updates for one year
Editing: seven; Published: January 2022
Executive Pool: 4597
Companies: 37 – Players covered include Abeona Therapeutics Inc.; ADMA Biologics, Inc.; Albumedix Ltd. ; Asklepios Biopharmaceutical, Inc.; Aspen Pharmacare Holdings Ltd. ; Baxter International Inc.; Bayer Healthcare AG; Bio Products Laboratory Ltd. ; BioDelivery Sciences International, Inc.; Biogen, Inc.; BioMarin Pharmaceutical Inc.; Biotest Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Catalyst Biosciences, Inc.; China Biologic Products Holdings, Inc.; Cosmo Pharmaceuticals N.V.; CSL Behring; Grifols International SA; Kamada Ltd. ; Kedrion Biopharma, Inc.; Medxbio Pte. ltd. ; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Corporation; Novo Nordisk A/S; Novozymes A/S; Octapharma SA; Portola Pharmaceuticals, Inc.; ProMetic Life Sciences, Inc.; rEVO Biologics, Inc.; Rockwell Medical; Sanquin; Shanghai RAAS Blood Products Co.,Ltd. ; Shire PLC; Teva Pharmaceutical Industries Ltd. ; The Medicines Company; Thermo Fisher Scientific, Inc.; Ventria Bioscience et al.
Cover: All major geographies and key segments
segments: Application (deep vein thrombosis, pulmonary embolism (PE), acute coronary syndrome, other applications); Drug class (albumin, prothrombin complex concentrates, antithrombin concentrates, other drug classes)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; UK; Spain; Russia; and rest of Europe); Asia Pacific (Australia; India; South Korea; and rest of Asia Pacific); Latin America (Argentina; Brazil; Mexico; and rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and rest of Middle East); and Africa.
Free Project Preview – This is an ongoing global program. Preview our research program before making a purchasing decision. We provide free access to qualified executives in strategy, business development, sales and marketing, and product management roles at featured companies. Insights provide insider access to business trends; competing brands; profiles of experts in the field; and market data models and much more. You can also create your own bespoke report using our MarketGlass™ platform which offers thousands of bytes of data with no obligation to purchase our report. Registry overview
Global critical care therapeutics market to reach $3.4 billion by 2026
Amid COVID-19 Crisis, Global Critical Care Therapeutics Market Estimated at US$2.9 billionis expected to reach a revised size of US$3.4 billion by 2026, growing at a CAGR of 2.6% over the analysis period. Albumin, one of the segments analyzed in the report, is expected to register a CAGR of 3% and reach US$1.6 billion at the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the economic crisis it induces, the growth of the prothrombin complex concentrates segment is readjusted to a revised CAGR of 2.1% for the next 7-year period.
The US market is estimated at $804.1 million in 2021, when China is expected to reach $671.3 million by 2026
The Critical Care Therapeutics market in the United States is estimated at US$804.1 million in the year 2021. Chinathe second largest economy in the world, is expected to reach a projected market size of US$671.3 million by 2026 with a CAGR of 4.9% over the analysis period. Other notable geographic markets include Japan and Canada, each forecasting growth of 0.6% and 1.9% respectively over the analysis period. In Europe, Germany is expected to grow at a CAGR of approximately 1.2%.
Segment of antithrombin concentrates to reach US$398.3 million by 2026
In the global antithrombin concentrates segment, UNITED STATES, Canada, Japan, China and Europe will drive the CAGR of 1.9% estimated for this segment. These regional markets representing a combined market size of US$260.9 million will reach a projected size of US$298 million at the end of the analysis period. China will remain among the most dynamic in this group of regional markets. After
Our MarketGlass™ platform is a free comprehensive knowledge center that can be custom configured to meet the intelligence needs of today’s busy business executives! This interactive, influencer-focused research platform is at the heart of our core research engagements and draws on the unique perspectives of participating executives from around the world. Features include – enterprise-wide peer-to-peer collaborations; overviews of research programs relevant to your business; 3.4 million profiles of experts in the field; profiles of competitive companies; interactive research modules; custom report generation; follow market trends; competing brands; create and publish blogs and podcasts using our primary and secondary content; follow domain events around the world; and much more. Client companies will have privileged access to the project’s data stacks. Currently used by over 67,000 domain experts worldwide.
About Global Industry Analysts, Inc. and StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher, the only influencer-focused market research company in the world. Proudly serving over 42,000 clients in 36 countries, GIA has been recognized for its accurate forecasting of markets and industries for over 33 years.
Director, Corporate Communications
Global Industry Analysts, Inc.
Join our group of experts
Connect with us on LinkedIn
Follow us on twitter
Journalists and media
Show original content to download multimedia:https://www.prnewswire.com/news-releases/valued-to-be-3-4-billion-by-2026–critical-care-therapeutics-slated-for-robust-growth-worldwide-301574699.html
SOURCE Global Industry Analysts, Inc.